Dr. David Pamies, a Postdoc in the Department of Physiology at Lausanne University, Switzerland was awarded the €100,000 LRI Innovative Science award, one of Europe’s largest research grants for early career scientists, at the award ceremony of Cefic’s 20th Annual Long-Range Initiative (LRI) Workshop in Brussels on November 14, 2018.
David Pamies got his master in Bioengineering and a PhD at the Miguel Hernandez University. The focus of his PhD research was to elucidate the role of neuropathy target esterase (NTE) in the differentiation processes using mouse embryonic stem cells in order to determine their role as a possible target in mammalian embryonic development toxicity, and human NT2 cells to identify the role of NTE in the processes of differentiation to form the neuroectoderm. Thus, his research was mainly focused on the use of in vitro systems to study neurodevelopmental processes. He also was working one year in the IHCP (European Commission). During his trainee period at the European Commission Joint Research Centre (JRC), He worked on new 3D models to assess developmental neurotoxicity (DNT). Afterwards, he joined the Centre for Alternatives to Animal Testing in January 2013, where he worked for five years, first as a postdoc and afterwards as a research associate on developing and application of an iPSC-derived 3D human brain micro physiological system to study DNT, encephalitis, virus infection, Parkinson disease (PD) and other conditions. Now, he is working on the use of new in vitro technologies to quantify adverse outcome pathways (AOPs) to help regulatory decision-making.
